Mutations

48 drugs in development·37 companies·1 clinical trial

Drug Pipeline by Phase

Approved(4)

Phase 3(6)

Drug	Company
aav2-hrpe65v2	Spark Therapeutics, Inc. (SPARK)
AL050	Alector, Inc. (ALEC)
hmpl-306	HUTCHMED (China) Ltd (HMDCF)
loxo-305	LOXO ONCOLOGY, INC. (LOXO)
otl-104	Orchard Therapeutics plc (ORTX)
otl-204	Orchard Therapeutics plc (ORTX)

Phase 2(8)

Drug	Company
BDTX-1535	Black Diamond Therapeutics, Inc. (BDTX)
mas825	Novartis AG (NVS)
MAS825	Novartis AG (NVS)
Mivavotinib (CB-659, formerly TAK-659)	Calithera Biosciences, Inc. (CALA)
poziotinib	Assertio Holdings, Inc. (ASRT)
Sapanisertib (CB-228, formerly TAK-228)	Calithera Biosciences, Inc. (CALA)
Telaglenastat (CB-839)	Calithera Biosciences, Inc. (CALA)
tipifarnib	Kura Oncology, Inc. (KURA)

Phase 1(9)

Drug	Company
ATRN-119	Aprea Therapeutics, Inc. (APRE)
BGB-53038	ENANTA PHARMACEUTICALS INC (ENTA)
CGT6297	Cogent Biosciences, Inc. (COGT)
enozertinib	Oric Pharmaceuticals, Inc. (ORIC)
IDE705 (GSK101)	IDEAYA Biosciences, Inc. (IDYA)
idh305	NOVARTIS AG (NVSEF)
idh305	Novartis AG (NVS)
lx101	SAB BIOTHERAPEUTICS, INC. (SABS)
ze46-0134	Rani Therapeutics Holdings, Inc. (RANI)

Preclinical(10)

Drug	Company
aav.103	Decibel Therapeutics, Inc. (DBTX)
aav.105	Decibel Therapeutics, Inc. (DBTX)
Fourth-Generation EGFR Inhibitor	Theseus Pharmaceuticals, Inc. (THRX)
KRAS program	Cogent Biosciences, Inc. (COGT)
mrtx1133	Mirati Therapeutics, Inc. (MRTX)
Pan-mutant BRAF degrader program (proprietary)	Nurix Therapeutics, Inc. (NRIX)
Pan-mutant BRAF program (mutant BRAF degraders)	Nurix Therapeutics, Inc. (NRIX)
pan-mutant pi3kα inhibitor	OnKure Therapeutics, Inc. (OKUR)
rad52 inhibitor	Rain Oncology Inc. (RAIN)
THE-349	Theseus Pharmaceuticals, Inc. (THRX)

Unknown(2)

Drug	Company
ADXS-HOT	Ayala Pharmaceuticals, Inc. (ADXS)
GBA1 discovery program	Camp4 Therapeutics Corp (CAMP)

Phase 1/Phase 2(8)

Drug	Company
achma3	APPLIED GENETIC TECHNOLOGIES CORP (AGTC)
achmb3	APPLIED GENETIC TECHNOLOGIES CORP (AGTC)
brimarafenib	SpringWorks Therapeutics, Inc. (SWTX)
db-oto	REGENERON PHARMACEUTICALS, INC. (REGN)
dcc-3116	Deciphera Pharmaceuticals, Inc. (DCPH)
envometinib	Immuneering Corp (IMRX)
lx2022	Lexeo Therapeutics, Inc. (LXEO)
pbgene-dmd	PRECISION BIOSCIENCES INC (DTIL)

Phase 2/Phase 3(1)

Drug	Company
sil204	Silexion Therapeutics Corp (SLXN)

BioSniper tracks 48 drugs in development for Mutations across 37 companies.

There are 1 clinical trial targeting Mutations tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.